Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis
CONCLUSION: However, further causality assessment is required to confirm the association of these drugs with identified potential signals.PMID:37990902 | DOI:10.2174/0115748863276447231108092936 (Source: Current Drug Safety)
Source: Current Drug Safety - November 22, 2023 Category: Drugs & Pharmacology Authors: Sourabh Raghuvanshi Mohammad Akhlaquer Rahman Mahesh Kumar Posa Anoop Kumar Source Type: research
Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis
CONCLUSION: However, further causality assessment is required to confirm the association of these drugs with identified potential signals.PMID:37990902 | DOI:10.2174/0115748863276447231108092936 (Source: Current Drug Safety)
Source: Current Drug Safety - November 22, 2023 Category: Drugs & Pharmacology Authors: Sourabh Raghuvanshi Mohammad Akhlaquer Rahman Mahesh Kumar Posa Anoop Kumar Source Type: research
Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis
CONCLUSION: However, further causality assessment is required to confirm the association of these drugs with identified potential signals.PMID:37990902 | DOI:10.2174/0115748863276447231108092936 (Source: Current Drug Safety)
Source: Current Drug Safety - November 22, 2023 Category: Drugs & Pharmacology Authors: Sourabh Raghuvanshi Mohammad Akhlaquer Rahman Mahesh Kumar Posa Anoop Kumar Source Type: research
Canagliflozin ameliorates high glucose-induced apoptosis in NRK-52E cells via inhibiting oxidative stress and activating AMPK/mTOR-mediated autophagy
CONCLUSION: Canagliflozin effectively ameliorate HG-induced apoptosis of NRK-52E cells in vitro that involved its antioxidant effect and induction of autophagy through the AMPK/mTOR pathway.PMID:37976004 | DOI:10.1007/s11033-023-08855-x (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - November 17, 2023 Category: Molecular Biology Authors: Hong Liu Weidong Chen Sheng Wan Ye Chen Mengjing Fu Zengsi Wang Fei Xiong Yanmin Zhang Source Type: research
Canagliflozin ameliorates high glucose-induced apoptosis in NRK-52E cells via inhibiting oxidative stress and activating AMPK/mTOR-mediated autophagy
CONCLUSION: Canagliflozin effectively ameliorate HG-induced apoptosis of NRK-52E cells in vitro that involved its antioxidant effect and induction of autophagy through the AMPK/mTOR pathway.PMID:37976004 | DOI:10.1007/s11033-023-08855-x (Source: Mol Biol Cell)
Source: Mol Biol Cell - November 17, 2023 Category: Molecular Biology Authors: Hong Liu Weidong Chen Sheng Wan Ye Chen Mengjing Fu Zengsi Wang Fei Xiong Yanmin Zhang Source Type: research
Canagliflozin ameliorates high glucose-induced apoptosis in NRK-52E cells via inhibiting oxidative stress and activating AMPK/mTOR-mediated autophagy
CONCLUSION: Canagliflozin effectively ameliorate HG-induced apoptosis of NRK-52E cells in vitro that involved its antioxidant effect and induction of autophagy through the AMPK/mTOR pathway.PMID:37976004 | DOI:10.1007/s11033-023-08855-x (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - November 17, 2023 Category: Molecular Biology Authors: Hong Liu Weidong Chen Sheng Wan Ye Chen Mengjing Fu Zengsi Wang Fei Xiong Yanmin Zhang Source Type: research
Canagliflozin ameliorates high glucose-induced apoptosis in NRK-52E cells via inhibiting oxidative stress and activating AMPK/mTOR-mediated autophagy
CONCLUSION: Canagliflozin effectively ameliorate HG-induced apoptosis of NRK-52E cells in vitro that involved its antioxidant effect and induction of autophagy through the AMPK/mTOR pathway.PMID:37976004 | DOI:10.1007/s11033-023-08855-x (Source: Mol Biol Cell)
Source: Mol Biol Cell - November 17, 2023 Category: Molecular Biology Authors: Hong Liu Weidong Chen Sheng Wan Ye Chen Mengjing Fu Zengsi Wang Fei Xiong Yanmin Zhang Source Type: research
Canagliflozin ameliorates high glucose-induced apoptosis in NRK-52E cells via inhibiting oxidative stress and activating AMPK/mTOR-mediated autophagy
CONCLUSION: Canagliflozin effectively ameliorate HG-induced apoptosis of NRK-52E cells in vitro that involved its antioxidant effect and induction of autophagy through the AMPK/mTOR pathway.PMID:37976004 | DOI:10.1007/s11033-023-08855-x (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - November 17, 2023 Category: Molecular Biology Authors: Hong Liu Weidong Chen Sheng Wan Ye Chen Mengjing Fu Zengsi Wang Fei Xiong Yanmin Zhang Source Type: research
Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation
In this study, we used hypobaric hypoxia-induced PAH mice model to demonstrate if canagliflozin could alleviate PAH and prevent pulmonary vessel remodeling. We found that daily canagliflozin administration significantly improved survival in mice with hypobaric hypoxia-induced PAH compared to vehicle control. Canagliflozin treatment significantly reduced right ventricular systolic pressure and increased pulmonary acceleration time determined by hemodynamic assessments. Canagliflozin significantly reduced medial wall thickening and decreased muscularization of pulmonary arterioles compared to vehicle treated mice. In additio...
Source: Clinical and Experimental Hypertension - November 16, 2023 Category: Cardiology Authors: Luxun Tang Qi Cai Xiao Wang Xiaoyu Li Xiuchuan Li Lianglong Chen Yongjian Yang Source Type: research
Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation
In this study, we used hypobaric hypoxia-induced PAH mice model to demonstrate if canagliflozin could alleviate PAH and prevent pulmonary vessel remodeling. We found that daily canagliflozin administration significantly improved survival in mice with hypobaric hypoxia-induced PAH compared to vehicle control. Canagliflozin treatment significantly reduced right ventricular systolic pressure and increased pulmonary acceleration time determined by hemodynamic assessments. Canagliflozin significantly reduced medial wall thickening and decreased muscularization of pulmonary arterioles compared to vehicle treated mice. In additio...
Source: Clinical and Experimental Hypertension - November 16, 2023 Category: Cardiology Authors: Luxun Tang Qi Cai Xiao Wang Xiaoyu Li Xiuchuan Li Lianglong Chen Yongjian Yang Source Type: research
Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation
In this study, we used hypobaric hypoxia-induced PAH mice model to demonstrate if canagliflozin could alleviate PAH and prevent pulmonary vessel remodeling. We found that daily canagliflozin administration significantly improved survival in mice with hypobaric hypoxia-induced PAH compared to vehicle control. Canagliflozin treatment significantly reduced right ventricular systolic pressure and increased pulmonary acceleration time determined by hemodynamic assessments. Canagliflozin significantly reduced medial wall thickening and decreased muscularization of pulmonary arterioles compared to vehicle treated mice. In additio...
Source: Clinical and Experimental Hypertension - November 16, 2023 Category: Cardiology Authors: Luxun Tang Qi Cai Xiao Wang Xiaoyu Li Xiuchuan Li Lianglong Chen Yongjian Yang Source Type: research
Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation
In this study, we used hypobaric hypoxia-induced PAH mice model to demonstrate if canagliflozin could alleviate PAH and prevent pulmonary vessel remodeling. We found that daily canagliflozin administration significantly improved survival in mice with hypobaric hypoxia-induced PAH compared to vehicle control. Canagliflozin treatment significantly reduced right ventricular systolic pressure and increased pulmonary acceleration time determined by hemodynamic assessments. Canagliflozin significantly reduced medial wall thickening and decreased muscularization of pulmonary arterioles compared to vehicle treated mice. In additio...
Source: Clinical and Experimental Hypertension - November 16, 2023 Category: Cardiology Authors: Luxun Tang Qi Cai Xiao Wang Xiaoyu Li Xiuchuan Li Lianglong Chen Yongjian Yang Source Type: research
Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation
In this study, we used hypobaric hypoxia-induced PAH mice model to demonstrate if canagliflozin could alleviate PAH and prevent pulmonary vessel remodeling. We found that daily canagliflozin administration significantly improved survival in mice with hypobaric hypoxia-induced PAH compared to vehicle control. Canagliflozin treatment significantly reduced right ventricular systolic pressure and increased pulmonary acceleration time determined by hemodynamic assessments. Canagliflozin significantly reduced medial wall thickening and decreased muscularization of pulmonary arterioles compared to vehicle treated mice. In additio...
Source: Clinical and Experimental Hypertension - November 16, 2023 Category: Cardiology Authors: Luxun Tang Qi Cai Xiao Wang Xiaoyu Li Xiuchuan Li Lianglong Chen Yongjian Yang Source Type: research
Protective effect of canagliflozin on post-resuscitation myocardial function in a rat model of cardiac arrest
Currently, most patients with cardiac arrest (CA) show reversible myocardial dysfunction, hemodynamic instability, systemic inflammation and other pathophysiological state in early stage of resuscitation, some... (Source: Intensive Care Medicine Experimental)
Source: Intensive Care Medicine Experimental - November 15, 2023 Category: Surgery Authors: Tianfeng Hua, Yuqian Chu, Minjie Wang, Yijun Zhang, Wei Shi, Qihui Huang, Liangliang Zhang and Min Yang Tags: Research Articles Source Type: research
SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review
Clin Ther. 2023 Nov 9:S0149-2918(23)00406-X. doi: 10.1016/j.clinthera.2023.10.014. Online ahead of print.ABSTRACTPURPOSE: One in seven Americans is at risk for chronic kidney disease (CKD). For decades, the only treatment proven to slow progression of CKD was the use of renin-angiotensin-aldosterone system inhibitors. Based on promising secondary kidney outcomes in the cardiovascular outcome trials with sodium-glucose co-transporter-2 inhibitors, kidney outcome trials in patients with CKD were published for canagliflozin, dapagliflozin, and empagliflozin.METHODS: A literature search was conducted of PubMed using the MeSH t...
Source: Clinical Therapeutics - November 11, 2023 Category: Drugs & Pharmacology Authors: Rebecca Maxson Jessica Starr Jeanna Sewell Claretha Lyas Source Type: research
